Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25138770 |
US |
2 | 1 |
Dermatitis atopic, Erythema, Pruritus, Skin haemorrhage, Injection site swelling, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2 | 25138818 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3 | 25138903 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 4 | 25138914 |
US |
5 | 2 |
Dermatitis atopic, Skin swelling, |
||||
DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, GUAIFENESIN, |
||||
| 5 | 25139017 |
US |
69 | 2 |
Intervertebral disc protrusion, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 6 | 25139062 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 7 | 25139113 |
US |
26 | 2 |
Dermatitis atopic, Product dose omission issue, Cholecystectomy, |
||||
DUPILUMAB, |
||||
| 8 | 25139114 |
US |
59 | 1 |
Rash pruritic, Rash erythematous, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 9 | 25139542 |
US |
1 | 1 |
Pericarditis, Condition aggravated, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 10 | 25141403 |
US |
2 | 1 |
Dermatitis atopic, Dry skin, Skin exfoliation, Therapeutic response shortened, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 11 | 25141415 |
US |
4 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 12 | 25141460 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 13 | 25141483 |
US |
42 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 14 | 25141495 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 15 | 25141509 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 16 | 25141527 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 17 | 25141535 |
US |
4 | 1 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 18 | 25141537 |
US |
21 | 2 |
Illness, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 19 | 25141540 |
US |
64 | 2 |
Dermatitis atopic, Neurodermatitis, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 20 | 25141557 |
US |
64 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 21 | 25141562 |
US |
24 | 2 |
Dermatitis atopic, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 22 | 25141563 |
US |
58 | 2 |
Impaired quality of life, Sleep disorder due to a general medical condition, Eye irritation, Dermatitis atopic, Skin discomfort, Rash, Injection site reaction, |
||||
DUPILUMAB, |
||||
| 23 | 25141581 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 24 | 25141589 |
US |
44 | 1 |
Dermatitis atopic, Stress at work, Pruritus, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 25 | 25141594 |
US |
69 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 26 | 25141613 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 27 | 25141623 |
US |
21 | 1 |
Skin irritation, Pruritus, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 28 | 25141671 |
US |
2 | |
Dermatitis atopic, Sensitivity to weather change, |
||||
DUPILUMAB, |
||||
| 29 | 25141676 |
US |
19 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 30 | 25141683 |
US |
4 | 1 |
Dermatitis atopic, Pruritus, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 31 | 25141912 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 32 | 25142028 |
US |
9 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 33 | 25142031 |
US |
69 | 1 |
Injection site pain, Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 34 | 25142554 |
US |
2 | |
Dermatitis atopic, Dry skin, Eyelid skin dryness, |
||||
DUPILUMAB, |
||||
| 35 | 25142813 |
US |
3 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 36 | 25138131 |
US |
3 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 37 | 25138132 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 38 | 25138135 |
US |
3 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 39 | 25138207 |
US |
53 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 40 | 25138258 |
US |
43 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 41 | 25138376 |
US |
47 | 1 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 42 | 25138378 |
US |
61 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 43 | 25138411 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, MUPIROCIN, MUPIROCIN CALCIUM, MOMETASONE FUROATE, MOMETASONE, PIMECROLIMUS, |
||||
| 44 | 25138440 |
US |
79 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 45 | 25138461 |
US |
24 | 1 |
Dermatitis atopic, Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 46 | 25138474 |
US |
57 | 2 |
Dermatitis atopic, Pruritus, Skin burning sensation, Rash erythematous, Peripheral swelling, |
||||
DUPILUMAB, CARIPRAZINE, SERTRALINE HYDROCHLORIDE, |
||||
| 47 | 25138617 |
US |
62 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 48 | 25138643 |
US |
||
Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 49 | 25138666 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 50 | 25137169 |
US |
49 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, |
||||
| 51 | 25137190 |
US |
15 | 2 |
Dermatitis atopic, Eyelid skin dryness, Erythema of eyelid, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 52 | 25137196 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 53 | 25137228 |
US |
51 | 2 |
Skin fissures, Psoriasis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 54 | 25137269 |
US |
8 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 55 | 25137270 |
US |
29 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 56 | 25137279 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 57 | 25137301 |
US |
30 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 58 | 25137302 |
US |
21 | 2 |
Discomfort, Sleep disorder due to a general medical condition, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 59 | 25137381 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 60 | 25137429 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 61 | 25137470 |
US |
54 | 1 |
Pruritus, Therapeutic response shortened, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 62 | 25137611 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 63 | 25137802 |
US |
41 | 2 |
Dermatitis atopic, Erythema, Skin swelling, Pruritus, |
||||
DUPILUMAB, |
||||
| 64 | 25137807 |
US |
19 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 65 | 25138020 |
US |
25 | 2 |
Pruritus, Erythema, Dermatitis atopic, Eye irritation, |
||||
DUPILUMAB, |
||||
| 66 | 25138089 |
US |
11 | 2 |
Dry skin, Injection site paraesthesia, Injection site hypoaesthesia, Pruritus, Dermatitis atopic, Skin weeping, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 67 | 25132057 |
US |
36 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 68 | 25132058 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 69 | 25132059 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 70 | 25132163 |
US |
15 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 71 | 25132167 |
US |
29 | 2 |
Urticaria, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 72 | 25132187 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 73 | 25132290 |
US |
32 | 2 |
Injection site pain, Dermatitis atopic, Therapeutic response decreased, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 74 | 25132295 |
US |
12 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 75 | 25132304 |
US |
48 | 1 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 76 | 25132312 |
US |
12 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 77 | 25132491 |
US |
67 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 78 | 25132496 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 79 | 25132512 |
US |
67 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 80 | 25132515 |
US |
29 | 2 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 81 | 25132539 |
US |
39 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 82 | 25132540 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 83 | 25132592 |
US |
60 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 84 | 25132658 |
US |
58 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 85 | 25132703 |
US |
42 | 2 |
Pneumonia, Sepsis, Anaemia, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 86 | 25133391 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 87 | 25133393 |
US |
5 | 1 |
Dermatitis atopic, Dry skin, Skin fissures, |
||||
DUPILUMAB, |
||||
| 88 | 25133396 |
US |
41 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 89 | 25133405 |
US |
25 | 2 |
Dermatitis atopic, Therapeutic response decreased, Eczema, |
||||
DUPILUMAB, |
||||
| 90 | 25133913 |
US |
59 | 2 |
Stress, Swollen tongue, Lacrimation increased, Visual impairment, Pain, Tongue biting, Oropharyngeal pain, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 91 | 25133945 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 92 | 25133952 |
US |
2 | |
Hidradenitis, Condition aggravated, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 93 | 25133971 |
US |
67 | 1 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, GABAPENTIN, |
||||
| 94 | 25134002 |
US |
55 | 2 |
Cheilitis, Drug hypersensitivity, Lip dry, Dry skin, Pruritus, Dry eye, Eye irritation, Dermatitis atopic, Condition aggravated, Rash, |
||||
DUPILUMAB, |
||||
| 95 | 25134009 |
US |
18 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, ERGOCALCIFEROL, MAGNESIUM, PAROXETINE HYDROCHLORIDE, |
||||
| 96 | 25134010 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 97 | 25134011 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 98 | 25134016 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 99 | 25134038 |
US |
51 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 100 | 25134059 |
US |
60 | 1 |
Allergy to animal, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28